Welcome to our dedicated page for Corvus Pharmaceu news (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceu stock.
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a clinical-stage biopharmaceutical company based in South San Francisco, California that focuses on immunotherapy for cancer and immune diseases. Company news frequently highlights progress with its lead ITK inhibitor, soquelitinib, and other clinical-stage candidates in oncology and immunology.
Investors following CRVS news can expect updates on clinical trial milestones, including the registration Phase 3 trial of soquelitinib in relapsed/refractory peripheral T cell lymphoma (PTCL) and randomized trials in atopic dermatitis. Corvus regularly reports interim and final data from Phase 1 and Phase 1b/2 studies, such as results in T cell lymphomas and atopic dermatitis, as well as presentations at major medical meetings like the American Society of Hematology (ASH), the European Society for Medical Oncology (ESMO) and rheumatology congresses.
News releases also cover business updates and financial results, where the company discusses its development strategy for ITK inhibition across cancer and immune diseases, cash runway, and collaborations. Additional announcements may describe progress with ciforadenant in metastatic renal cell cancer, the partner-led mupadolimab program in non-small cell lung cancer, and the Autoimmune Lymphoproliferative Syndrome (ALPS) trial conducted with the National Institute of Allergy and Infectious Diseases.
This CRVS news page aggregates these disclosures so readers can review clinical data announcements, regulatory designations, collaboration updates and corporate events in one place. For those tracking immuno-oncology and immune disease pipelines, Corvus news provides insight into the evolution of its ITK platform and related investigational therapies.
Corvus Pharmaceuticals announced an investor conference call regarding CPI-818, an ITK inhibitor, on December 12, 2022, from 4:30 PM ET. The call will provide updates on data presented at the 64th ASH Annual Meeting and progress in the company's development programs. Highlights include results from the Phase 1/1b clinical trial targeting T-cell lymphomas and autoimmune diseases.
The ASH presentation will feature data on Th1 skewing in normal T cells, presented by Dr. Ryan Wilcox. Access details for the call and a 90-day webcast replay are available on the Corvus website.
On November 12, 2022, James T. Rosenbaum, MD, Senior VP of Research at Corvus Pharmaceuticals (Nasdaq: CRVS), received the Distinguished Service Award from the American College of Rheumatology (ACR), recognizing his contributions to rheumatology. Dr. Rosenbaum, who joined Corvus in July 2022, leads the development of CPI-818, an ITK inhibitor targeting immune disorders. Under his guidance, new clinical studies for CPI-818 are being prepared, with results from a Phase 1/1b trial to be shared at the upcoming ASH Annual Meeting from December 10-13, 2022.
Corvus Pharmaceuticals (CRVS) reported its Q3 2022 financial results and provided a business update, highlighting key milestones in drug development. The company focuses on CPI-818 for T cell lymphoma, with ongoing clinical trials showing promising patient responses and upcoming data to be presented at the ASH annual meeting. Additionally, a Phase 1b/2 trial for ciforadenant in renal cell cancer has commenced, and a Phase 1/1b trial for mupadolimab is approved in China. As of September 30, 2022, Corvus had cash reserves of $49.6 million, down from $69.5 million in 2021, with expected operational funding until early 2024.
Corvus Pharmaceuticals (NASDAQ: CRVS) will present new data from its Phase 1/1b trial of CPI-818, an ITK inhibitor, at the 64th American Society of Hematology Annual Meeting from December 10-13, 2022. The presentation will take place on December 12, 2022, at 6:00 PM ET, detailing CPI-818's effects on T-cell lymphoma and its potential in treating autoimmune diseases. Following the presentation, the company will host a conference call at 4:30 PM ET on the same day to discuss the findings. For further details, visit www.corvuspharma.com.
Corvus Pharmaceuticals (CRVS) will host a conference call and webcast on November 3, 2022, at 4:30 pm ET to report its third-quarter 2022 financial results and provide a business update. Interested participants can join the call by dialing specific numbers, and a replay will be available on the company's website for 90 days. Corvus focuses on developing innovative therapies, with its lead candidate CPI-818 undergoing clinical trials for T-cell lymphomas. Other programs include CPI-444 and CPI-006, targeting critical pathways in cancer treatment.
Corvus Pharmaceuticals (Nasdaq: CRVS) announced the launch of a Phase 1b/2 clinical trial for ciforadenant, aimed at treating metastatic renal cell cancer (RCC). The trial, conducted with the Kidney Cancer Research Consortium, will enroll up to 60 patients, evaluating ciforadenant combined with ipilimumab and nivolumab. The primary endpoints focus on safety and anti-tumor activity, with preliminary results expected early in the trial. The company highlights previous positive data on ciforadenant's efficacy, providing a strong rationale for this investigation.
Corvus Pharmaceuticals announced the approval of an IND application to initiate a Phase 1/1b clinical trial for mupadolimab in China, in partnership with Angel Pharmaceuticals. Mupadolimab targets CD73 to activate immune responses in patients with relapsed refractory non-small cell lung cancer (NSCLC) and head and neck squamous cell cancers (HNSCC). The trial aims to evaluate the drug’s safety, pharmacokinetics, and efficacy, with plans for a subsequent randomized Phase 2 trial in combination with pembrolizumab and chemotherapy.
Corvus Pharmaceuticals (Nasdaq: CRVS) has announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. CEO Richard A. Miller will present a pre-recorded corporate overview, available on-demand starting September 12 at 7:00 am ET. The presentation will be accessible for 90 days on the Corvus investor relations webpage. Corvus focuses on developing innovative treatments for T-cell lymphomas, notably its lead candidate CPI-818 and other programs such as ciforadenant and mupadolimab.
Corvus Pharmaceuticals (CRVS) provided a business update and financial results for Q2 2022. The company is prioritizing CPI-818 for T cell lymphomas and related autoimmune diseases, showing promising early clinical data. Additionally, it plans a Phase 2 trial for ciforadenant in metastatic renal cell cancer with the Kidney Cancer Clinical Trials Consortium in Q3 2022. However, development of mupadolimab for lung cancer is paused to focus resources. As of June 30, 2022, cash reserves amounted to $56.7 million, projected to fund operations into early 2024.
Corvus Pharmaceuticals (Nasdaq: CRVS) announced a conference call and webcast scheduled for August 8, 2022, at 4:30 PM ET to report second quarter 2022 financial results and provide a business update. The call can be accessed via phone or through a live webcast on Corvus' investor relations page, with a replay available for 90 days. Corvus focuses on developing novel therapies, including mupadolimab (CPI-006) and CPI-818, for the treatment of various cancers.